Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
TRIPATH IMAGING INC (TPTH)
|
Add to portfolio |
|
|
|
| Price: |
$9.19
| | Metrics |
| OS: |
39.0
|
M
| |
8
|
% ROE
|
| Market cap: |
$358
|
M
| |
12
|
% ROIC
|
|
Net cash:
|
$27.3
|
M
| |
$0.70
|
per share
|
|
EV:
|
$331
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$10.2
|
M
| |
32.6
|
x EV/EBITDA
|
|
EBIT
|
$5.2
|
M
| |
63.4
|
x EV/EBIT
|
| EPS |
$0.14
| |
65.0
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-05 | Dec-31-04 | Dec-31-03 | Dec-31-02 | Dec-31-01 | Dec-31-00 |
| Revenues | 86.0 | 68.5 | 53.8 | 37.5 | 27.0 | 32.7 |
| Revenue growth | 25.5% | 27.4% | 43.4% | 38.7% | -17.3% | |
| Cost of goods sold | 26.0 | 21.2 | 18.4 | 14.9 | 13.1 | 16.1 |
| Gross profit | 59.9 | 47.3 | 35.4 | 22.6 | 13.9 | 16.5 |
| Gross margin | 69.7% | 69.0% | 65.8% | 60.2% | 51.5% | 50.6% |
| Sales and marketing | 24.4 | 18.6 | 18.3 | 19.9 | 18.7 | 5.7 |
| Research and development | 12.4 | 11.3 | 8.9 | 7.5 | 5.9 | 8.8 |
| General and administrative | 13.6 | 13.1 | 11.7 | 10.9 | 10.1 | 18.1 |
| EBITA | 7.1 | 1.2 | -8.1 | -17.7 | -21.9 | -16.2 |
| EBITA margin | 8.2% | 1.7% | -15.1% | -47.1% | -80.9% | -49.5% |
| Amortization of intangibles | 0.9 | 0.8 | 0.8 | 0.8 | 0.8 | 0.8 |
| EBIT | 6.2 | 0.3 | -8.9 | -18.5 | -22.7 | -17.0 |
| EBIT margin | 7.2% | 0.5% | -16.6% | -49.3% | -84.0% | -52.0% |
| Pre-tax income | 6.8 | 0.6 | -8.5 | -18.1 | -21.7 | -17.4 |
| Income taxes | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 4.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 6.5 | 0.6 | -8.5 | -18.1 | -21.7 | -17.4 |
| Net margin | 7.6% | 0.9% | -15.9% | -48.2% | -80.2% | -53.2% |
| |
| Diluted EPS | $0.17 | $0.02 | ($0.23) | ($0.48) | ($611.27) | ($596.11) |
| Shares outstanding (diluted) | 38.2 | 30.3 | 37.1 | 37.6 | 0.0 | 0.0 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|